

## COVID-19 in Africa: What else?

C. Sokhna<sup>1</sup>, S. Brah<sup>2</sup>, A. Djimde<sup>3</sup>, N. Mouffok<sup>4</sup>, M. Zahraoui<sup>5</sup>, A. Ould Mohamed Salem Boukhary<sup>6</sup>, I. Bitam<sup>7</sup>, B. Cisse<sup>8</sup>, M. A. Thera<sup>3</sup>, J.-B. Lekana-Douki<sup>9</sup>, E. Adehossi<sup>10</sup>, M. Seydi<sup>11</sup>, J. Akiana<sup>12</sup>, J. Heikel<sup>5</sup>, J.-C. Lagier<sup>13,14</sup>, S. Mboup<sup>8</sup>, J.-J. Mouyembe-Tamfum<sup>15</sup> and P. Parola<sup>13,16</sup>

1) VITROME, Campus International IRD-UCAD, Dakar, Senegal, 2) Service de Médecine Interne, Hôpital Général de Référence, Niamey, Niger, 3) Malaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali, 4) Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Oran, Algeria, 5) Service de Médecine Interne, Clinique De Vinci, Casablanca, Morocco, 6) Université de Nouakchott Al Aasriya, Nouakchott, Mauritania, 7) Ecole Supérieure en Sciences de L'Aliment et des Industries Agroalimentaire, Direction Générale de La Recherche Scientifique et Développement Technologique, Ministère de L'enseignement Supérieur et de La Recherche Scientifique, Alger, Algeria, 8) Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal, 9) Département de Parasitologie-Mycologie, Université des Sciences de La Santé (USS) Libreville, UNEEREP-CIRMF, Franceville, Gabon, 10) Université Abdou Moumouni, Niamey, Niger, 11) Service de Maladies Infectieuses et Tropicale, Centre Hospitalier Universitaire de Fann, Université Cheikh Anta Diop, Dakar, Senegal, 12) Faculté des Sciences et Techniques/Université Marien NGOUABI de Brazzaville, Democratic Republic of the Congo, 13) University Hospital Institute IHU-Méditerranée Infection, Marseille, 14) Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France, 15) Département de Microbiologie, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo and 16) Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France

**Keywords:** Africa, azithromycin, Covid-19, hydroxychloroquine, SARS-cov-2

**Original Submission:** 1 October 2021; **Revised Submission:** 29 April 2022; **Accepted:** 2 May 2022

**Article published online:** 9 May 2022

**Corresponding author:** Philippe Parola, University Hospital Institute IHU-Méditerranée Infection, Marseille, France.  
E-mail: [philippe.parola@univ-amu.fr](mailto:philippe.parola@univ-amu.fr)

Dear Editor,

In Spring 2020, both WHO and the UN Economic Commission for Africa predicted that COVID-19 would take a heavy toll in

Africa. However, 10 months after the first cases in Africa were detected, mortality, probably the most significant way to measure the burden of COVID-19, was still low. It has remained at a low level by April 2022 (Table 1).

One could say that mortality tends to be higher in older populations, as the median age of Africa is 19.7 (compared to 42.5 in Europe and 38.6 in northern America). However, high mortality has also been reported in South Africa (median age 27). Also, while South Africa was one of the countries with the best laboratory facilities to confirm deaths related to COVID-19, laboratory facilities have rapidly increased in our other countries [1].

Factors which may explain the dampened course of COVID-19 in Africa have been discussed, ranging from genetic characteristics to immunological factors and even microbiota. However, after the first Chinese publications about the antiviral effects of chloroquine (CQ) and its derivatives against SARS-CoV2 and a preliminary trial in France [2], many African countries adopted CQ or hydroxychloroquine (HCQ) with or without azithromycin (AZ) to treat presumptive or confirmed COVID-19 cases. This, despite the WHO position and other published or retracted studies claiming that this regimen would not be effective or toxic.

More evidence came with the demonstration of a synergistic effect in vitro of the HCQ-AZ combination on SARS-CoV-2 and from observational studies with thousands of cases. Both HCQ and AZ are immunomodulators, which may prevent the “cytokine storm” of COVID-19. The HCQ antithrombotic effects might also be useful in the context of Covid-associated pulmonary embolism and coagulopathy. Finally, HCQ-AZ has been associated with a reduction in viral shedding, with potential public health effects by reducing the duration of contagiousness [2].

By the end of 2020, while in several African countries a pragmatic, safe use of CQ or HCQ with or without AZ had prevailed, Western countries were still awaiting the results of clinical trials to define their strategy, worrying about hypothetical side effects of HCQ-AZ, which has been used for decades, or were promoting other treatments (with no demonstrated efficacy) or standard care only, which may be limited when people are asked to remain at home by health authorities.

The dogma about the need randomized controlled trials (RCTs) to support therapeutic choice and public health decision is an issue. However, a Cochrane Library publication stated that observational studies and randomized controlled trials (RCTs) give the same results [3]. By April 2022, more than 400 studies had been published concerning CQ or HCQ, including about 313 peer reviewed, including in Senegal and Ghana, and about 339 comparing treatment and control groups [<https://c19hcq.com>]. Most of them are observational studies reporting that early

treatment shows positive results [4]. Interestingly, the supplementary material must be sometimes carefully reviewed to learn that HCQ was one of the most active drugs, as this had been omitted in the text and the summary.

Other factors, such as blood type, climate, and prevalence of obesity among the population, have to be assessed in order to provide more insights on COVID-19 epidemiological patterns in Africa. SARS-CoV-2 variant emergence may also be an issue [5]. The age structure of the population of our countries may also help explain differences in fatality rates across countries better than the mean age.

The use of HCQ-AZ for COVID-19 treatment and has resulted in political issues, academic discord, as well as passionate debates in the media and scientific journals about the efficacy or possible toxicity of CQ or HCQ. This, seen from an African perspective, where billions of doses have been dispensed in the past century, speaks volumes about the real safety of these drugs.

To date, most of the countries with the highest mortality from COVID-19 include the countries where the most negative media noise about CQ, HCQ or HCQ-AZ has been made, and this despite current higher percentage of population fully vaccinated (Table 1). Although the link between the widespread cost-effective use of CQ, HCQ or HCQ-AZ and the evolution of COVID-19 in Africa has not been yet demonstrated with certainty, it at least deserves to be discussed.

**TABLE 1. Covid-19 mortality (number of deaths/100,000 population) in selected African countries, including some where use of chloroquine hydroxychloroquine with or without azithromycin has prevailed to treat COVID-19. These African countries are those where the authors, as infectious disease and microbiology experts, have been involved in the COVID-19 pandemic response. South Africa, some European countries and the USA are presented as comparators. For an update and other countries, see <https://coronavirus.jhu.edu/data/mortality>**

	Mortality December, 2020	Mortality April, 2022	% Of population fully vaccinated April, 2022
Algeria	6.12	15.68	13.9
Democratic Republic of Congo	0.12	1.49	NA
Gabon	2.97	13.61	11.31
Mali	0.99	3.61	5.04
Mauritania	5.05	21.12	22.9
Morocco	18.29	43.41	63.32
Niger	0.36	1.28	6.4
Republic of the Congo	6.71	6.98	NA
Senegal	2.2	11.75	6.21
South Africa	33.08	169.17	30.8
Belgium	155.77	272.51	79.51
France	86.09	224.21	80.5
UK	96.44	256.79	73.22
USA	91.03	300.97	66.6

## Funding

No specific source of funding.

## Author contributions

Each author made substantial contributions to the conception, design, writing, and review of this article.

## Transparency declaration

The authors have no financial or non-financial actual or potential conflicts of interest.

## Author contributions

All authors made substantial contributions to the conception, design, writing, validation and review of this article. Philippe Parola Supervised the work.

## Acknowledgments

This manuscript has been edited by a native English speaker.

## References

- [1] Lalaoui R, Bakour S, Raoult D, Verger P, Sokhna C, Devaux C, et al. What could explain the late emergence of COVID-19 in Africa? *New Microbe. New Infect* 2020 Nov;38:100760. <https://doi.org/10.1016/j.nmni.2020.100760>.
- [2] Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol* 2020 Dec;16(12):1159–84. <https://doi.org/10.1080/1744666X.2021.1847640>.
- [3] Anglemeyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. *Cochrane Database Syst Rev* 2014 Apr 29;(4). <https://doi.org/10.1002/14651858.MR000034.pub2>. MR000034.
- [4] Million M, Lagier JC, Tissot-Dupont H, Ravaux I, Dhiver C, Tomei C, et al. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. *Rev Cardiovasc Med* 2021 Sep 24;22(3):1063–72. <https://doi.org/10.31083/j.rcm2203116>. PMID: 34565108.
- [5] Colson P, Parola P, Raoult D. The emergence, dynamics and significance of SARS-CoV-2 variants. *New Microbe. New Infect* 2022 Jan;45:100962. <https://doi.org/10.1016/j.nmni.2022.100962>. Epub 2022 Feb 1. PMID: 35127101; PMCID: PMC8806113.